Avacta is the proprietary owner of Affimer technology for the development of biotherapeutics, diagnostic tests and research reagents. Affimers represent a revolutionary alternative to the established antibody technology which dominates the drug industry despite its limitations. Avacta has made considerable progress towards its strategic goal to have a first-in-man Affimer therapeutic by the end of 2019. Meanwhile, its reagent business is continuing to deliver on three initial areas of strategic focus. There will be greater recognition of the long-term potential of Affimers in the enterprise value as Avacta signs more licensing/collaboration deals.
17 Oct 2016
Great strides towards strategic goals
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Great strides towards strategic goals
Avacta Group PLC (AVCT:LON) | 48.0 -0.8 (-3.5%) | Mkt Cap: 168.2m
- Published:
17 Oct 2016 -
Author:
Martin Hall -
Pages:
16
Avacta is the proprietary owner of Affimer technology for the development of biotherapeutics, diagnostic tests and research reagents. Affimers represent a revolutionary alternative to the established antibody technology which dominates the drug industry despite its limitations. Avacta has made considerable progress towards its strategic goal to have a first-in-man Affimer therapeutic by the end of 2019. Meanwhile, its reagent business is continuing to deliver on three initial areas of strategic focus. There will be greater recognition of the long-term potential of Affimers in the enterprise value as Avacta signs more licensing/collaboration deals.